A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
Terminated · Phase 1 · NCT05209295
Conditions: Hepatic Insufficiency, Neoplasms
At a glance
- Research payments reported, 2025
- $111
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 2
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Onureg (drug)
- Dates
- Started 2024-07-12; completion 2025-04-20
- Results posted
- Not yet
The purpose of this study is to evaluate the effect of moderate or severe liver impairment on the drug levels of oral azacitidine and the safety and tolerability of oral azacitidine in participants with myeloid malignancies.
From ClinicalTrials.gov, last updated 2026-01-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $111 in research payments for this study in 2025 (1 payments).
Products named: Vidaza
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Virginia Cancer Center $111
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.